GlassScriptPhysician profile
Tavon S Johnson
NPI 1871345009
$716.92
in general payments reported to CMS, 2019-2025
12 companies · $523 in 2025
The $523 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $194 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $279.68 | 2024-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $125.19 | 2024-2025 | Zerbaxa, Prevymis, Delstrigo |
| Aimmune Therapeutics, INC. | $81.78 | 2024-2025 | Vowst |
| Theratechnologies INC. | $44.19 | 2025 | Trogarzo, Egrifta |
| Melinta Therapeutics, LLC | $39.98 | 2024-2025 | Rezzayo, Kimyrsa |
| Smith+Nephew, INC. | $33.99 | 2025 | Collagenase Santyl |
| Viiv Healthcare Company | $31.19 | 2025 | Dovato |
| La Jolla Pharmaceutical Company | $24.49 | 2025 | Zevtera |
| Hartmann USA, INC. | $14.95 | 2025 | Zetuvit Plus 10x10 P10 |
| Paratek Pharmaceuticals, INC. | $14.52 | 2025 | Nuzyra |
| Alnylam Pharmaceuticals INC. | $13.85 | 2025 | Givlaari |
| Averitas Pharma INC. | $13.11 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tavon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.